Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) $ in Millions		3 Months Ended
		Apr. 03, 2022 USD ($) operatingSegment	Apr. 04, 2021 USD ($)
Revenue from External Customer [Line Items]
Revenues	[1]	$ 25,661	$ 14,516
Number of segments | operatingSegment		2
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1],[2]	$ 25,323	14,125
Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	338	391
BioNTech [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues		47
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		2,314	1,770
Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	605	530
Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,331	1,482
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		14,941	4,894
Vaccines [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		13,227	3,462
Vaccines [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	1,565	1,284
Vaccines [Member] | Nimenrix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		77	46
Vaccines [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		42	53
Vaccines [Member] | All other Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		29	49
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	3,191	1,886
Hospital [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,470	0
Hospital [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		210	192
Hospital [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		125	89
Hospital [Member] | IVIg Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	107	105
Hospital [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		104	94
Hospital [Member] | Medrol [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		76	99
Hospital [Member] | Fragmin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		70	71
Hospital [Member] | Vfend [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		65	80
Hospital [Member] | All other Anti-infectives [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		381	455
Hospital [Member] | All other Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		583	700
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,967	2,862
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,237	1,254
Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		268	267
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		234	229
Oncology [Member] | Zirabev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	147	86
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		128	123
Oncology [Member] | Xalkori [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		127	134
Oncology [Member] | Ruxience [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	124	98
Oncology [Member] | Retacrit [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	115	109
Oncology [Member] | Sutent [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		114	200
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		72	60
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		67	32
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		62	52
Oncology [Member] | Trazimera [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	52	45
Oncology [Member] | Besponsa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		51	50
Oncology [Member] | Braftovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		48	47
Oncology [Member] | Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		40	35
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		81	41
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,440	2,594
Internal Medicine [Member] | Eliquis [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,793	1,643
Internal Medicine [Member] | Premarin family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		102	143
Internal Medicine [Member] | BMP2 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		67	49
Internal Medicine [Member] | Toviaz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		54	57
Internal Medicine [Member] | Chantix / Champix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2	217
Internal Medicine [Member] | All other Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		423	484
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		963	824
Rare Disease [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		612	453
Rare Disease [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		112	112
Rare Disease [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		80	80
Rare Disease [Member] | Somavert [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		68	65
Rare Disease [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		66	89
Rare Disease [Member] | All other Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		25	26
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		821	1,065
Inflammation and Immunology (I&I) [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		372	538
Inflammation and Immunology (I&I) [Member] | Enbrel [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		280	319
Inflammation and Immunology (I&I) [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	135	177
Inflammation and Immunology (I&I) [Member] | All other I & I [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		$ 35	$ 31

[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A.

[2] At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.

[3] Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit, and Trazimera.

[4] Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.

[5] Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).

[6] Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.